Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for autoimmune and inflammatory disorders, presented first-in-human data for LFD-200, its novel subcutaneously administered ADC delivering a potent glucocorticoid directly to immune cells. The Phase 1 data, presented at EULAR 2026 in London, UK, demonstrated that LFD-200 was well tolerated in healthy participants and exhibited dose-responsive anti-inflammatory activity without affecting serum cortisol levels, a sensitive marker for systemic glucocorticoid toxicity.
LFD-200 is designed to deliver glucocorticoids selectively to immune cells, potentially avoiding the systemic side effects associated with conventional steroid therapies. The Phase 1 study initially enrolled healthy participants to assess safety, pharmacokinetics, and pharmacodynamics. Results showed no significant impact on cortisol levels, suggesting limited systemic exposure and reduced risk of adrenal suppression. Anti-inflammatory activity was observed in a dose-dependent manner, supporting further investigation in patient populations.
Dosing of patients with moderate to severe rheumatoid arthritis (RA) in the Phase 1 study is ongoing, with data expected by year-end 2026. The company aims to establish LFD-200 as a potential treatment option that could offer the efficacy of glucocorticoids without their typical side effects, such as weight gain, osteoporosis, and increased infection risk.
Lifordi leverages the success of ADC technology, traditionally used in oncology, to target immune cells. The company's platform extends beyond glucocorticoids to other payloads, including antisense oligonucleotides, siRNA, and small molecules. Backed by investors such as ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi is committed to transforming the treatment landscape for immune and inflammatory diseases.
For more information, visit www.lifordi.com.
